MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Arrowhead Pharmaceuticals Inc

Închisă

SectorSănătate

12.72 4.78

Rezumat

Modificarea prețului

24h

Curent

Minim

11.93

Maxim

12.82

Indicatori cheie

By Trading Economics

Venit

-1.9M

-175M

Vânzări

2.5M

2.5M

EPS

-1.39

Marjă de profit

-7,008.72

Angajați

609

EBITDA

4.9M

-148M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+232.79% upside

Dividende

By Dow Jones

Următoarele câștiguri

8 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

1.9B

Deschiderea anterioară

7.94

Închiderea anterioară

12.72

Sentimentul știrilor

By Acuity

29%

71%

87 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Arrowhead Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 sept. 2024, 10:38 UTC

Principalele dinamici ale pieței

Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran

Comparație

Modificare preț

Arrowhead Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

232.79% sus

Prognoză pe 12 luni

Medie 40.6 USD  232.79%

Maxim 80 USD

Minim 21 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruArrowhead Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

7

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 11.675Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

87 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.